Business
Amesite Announces Closing of Up To $7.8 Million Concurrent Registered Direct Offering and Private Placements Priced At-the-Market Under Nasdaq Rules
$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrantsDETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a
About this update from Amesite Inc.
$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants DETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors unregistered Series A-1 warrants to purchase up to 696,866 shares of common stock and unregistered Series A-2 warrants to purchase up to 696,866 shares of common stock. The warrants have an exercise price of $1.435 per share and will be exercisable beginning on the effective date of stockholder approval for the issuance of the shares issuable upon exercise of the warrants. The Series A-1 warrants will expire five years after the later of (i) effective date of the Resale Registration Statement (as defined below) and (ii) the date of stockholder approval and the Series A-2 warrants will expire eighteen months after the later of (i) effective date of the Resale Registration Statement (as defined below) and (ii) the date of stockholder approval. The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 696,866 shares of common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 696,866 shares of the Company’s common stock and Series A-2 warrants to purchase up to 696,866 shares of the Company’s common stock at a purchase price of $1.435 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants issued in the private placement have an exercise price of $1.435 per share and will be exercisable beginning on the effective date of stockholder approval for the issuance of the shares issuable upon exercise of the warrants. The Series A-1 warrants will expire five years after the later of (i) effective date of the Resale Registration Statement (as defined below) and (ii) the date of stockholder approval and the Series A-2 warrants will expire eighteen months after the later of (i) effective date of the Resale Registrati...